CoChat
Sign Up
Cited by 396SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Open access
Choi, Angela, Koch, Matthew, Wu, Kai, Chu, Laurence, Ma, LingZhi, Hill, Anna, Nunna, Naveen, Huang, Wenmei, Oestreicher, Judy, Colpitts, Tonya, Bennett, Hamilton, Legault, Holly, Paila, Yamuna, Nestorova, Biliana, Ding, Baoyu, Montefiori, David, Pajon, Rolando, Miller, Jacqueline M., Leav, Brett, Carfi, Andrea, McPhee, Roderick, Edwards, Darin K.·2021·Nature Medicine
DOI 10.1038/s41591-021-01527-yPMC PMC8604720
Open this paper in CoChat — free accountOpen PDF

Abstract

The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) with decreased susceptibility to neutralization has generated interest in assessments of booster doses and variant-specific vaccines. Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study ( NCT04405076 ) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing, this exploratory interim analysis includes preliminary descriptive results only of four booster groups (n = 20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned (P < 0.0001) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated. All boosters, including mRNA-1273, numerically increased neutralization titers against the wild-type D614G virus compared to peak titers against wild-type D614G measured 1 month after the primary series; significant increases were observed for mRNA-1273 and mRNA-1273.211 (P < 0.0001). In addition, all boosters increased neutralization titers against key VOCs and VOIs, including B.1.351, P.1. and B.1.617.2, that were statistically equivalent to peak titers measured after the primary vaccine series against wild-type D614G virus, with superior titers against some VOIs. This trial is ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01527-y

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Participant flow through the mRNA-1273 booster and mRNA-1273 variant booster cohorts. In the mRNA-1273 booster phase, 20 participants who had received two injections of 100-μg mRNA-1273 completed the blinded phase and who went on to receive a single booster dose of 50-μg mRNA-1273 were selected for this preliminary analysis, with selection based on completion of day 15 visit assessments and immunogenicity sample availability. In the mRNA-1273 variant booster phase, enrollment was site specific and was based on predefined inclusion/exclusion criteria. Administration of booster doses occurred in a sequential manner (mRNA-1273 variant booster phase, which included the mRNA-1273.351 (50 µg) cohort; the mRNA-1273.211 (50 µg) cohort; and the mRNA-1273.351 (20 µg) cohort). aUnblinded or not unblinded to assigned treatment in the blinded portion of the phase 2a mRNA-1273 trial. bFifteen participants declined to receive a booster. cThirteen participants declined to receive a booster. dTwenty-two participants declined to receive an mRNA-1273 primary vaccination.
Fig. 1 Participant flow through the mRNA-1273 booster and mRNA-1273 variant booster cohorts. In the mRNA-1273 booster phase, 20 participants who had received two injections of 100-μg mRNA-1273 completed the blinded phase and who went on to receive a single booster dose of 50-μg mRNA-1273 were selected for this preliminary analysis, with selection based on completion of day 15 visit assessments and immunogenicity sample availability. In the mRNA-1273 variant booster phase, enrollment was site specific and was based on predefined inclusion/exclusion criteria. Administration of booster doses occurred in a sequential manner (mRNA-1273 variant booster phase, which included the mRNA-1273.351 (50 µg) cohort; the mRNA-1273.211 (50 µg) cohort; and the mRNA-1273.351 (20 µg) cohort). aUnblinded or not unblinded to assigned treatment in the blinded portion of the phase 2a mRNA-1273 trial. bFifteen participants declined to receive a booster. cThirteen participants declined to receive a booster. dTwenty-two participants declined to receive an mRNA-1273 primary vaccination.CC BY · PubMed Central
Fig. 2 ARs within 7 d after booster dose. The percentage of participants who reported local (a) and systemic (b) ARs is shown for 20 participants who received a booster dose of mRNA-1273 (50 µg), 19 participants who received a booster dose of mRNA-1273.351 (20 µg), 19 participants who received a booster dose of mRNA-1273.351 (50 µg) and 20 participants who received a booster dose of mRNA-1273.211 (50 µg). One participant each in the mRNA-1273.351 50-µg and 20-µg groups did not report results for solicited ARs and were excluded from the analysis.
Fig. 2 ARs within 7 d after booster dose. The percentage of participants who reported local (a) and systemic (b) ARs is shown for 20 participants who received a booster dose of mRNA-1273 (50 µg), 19 participants who received a booster dose of mRNA-1273.351 (20 µg), 19 participants who received a booster dose of mRNA-1273.351 (50 µg) and 20 participants who received a booster dose of mRNA-1273.211 (50 µg). One participant each in the mRNA-1273.351 50-µg and 20-µg groups did not report results for solicited ARs and were excluded from the analysis.CC BY · PubMed Central
Fig. 3 Neutralization of wild-type D614G and B.1.351 by participant serum collected immediately before and after boosters, as measured by the lentiviral-based PsVN assay. Wild-type D614G neutralization (a) and B.1.351 neutralization (b) in a validated recombinant lentivirus-based SARS-CoV-2 pseudovirus assay by serum from participants (n = 20 participants per booster cohort). Sera samples were collected immediately before receiving a booster (day 1) and on days 15 and 29 after the booster dose of mRNA-1273 (50 µg), mRNA-1273.351 (50 or 20 µg) or mRNA-1273.211 (50 µg). Participant sera in the mRNA-1273 (50 µg) booster group were not assessed in the B.1.351 assay. Data are presented as the geometric mean neutralizing antibody titers with 95% confidence intervals. The titers for individual participants are indicated with circles. The fold increases in titers measured at days 15 and 29 versus titers measured before the booster dose are shown. The horizonal dotted lines indicate the LLOQ. Generalized linear model was used to compare neutralization titers among groups; log10 titer was regressed on group, and an individual-specific random effect was included to account for individual specific variability. Two-sided t-test was used for post hoc group comparisons. Sidak’s method was used to adjust the P values for multiple comparisons. Statistical significance was determined at α < 0.01. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NAb, neutralizing antibody.
Fig. 3 Neutralization of wild-type D614G and B.1.351 by participant serum collected immediately before and after boosters, as measured by the lentiviral-based PsVN assay. Wild-type D614G neutralization (a) and B.1.351 neutralization (b) in a validated recombinant lentivirus-based SARS-CoV-2 pseudovirus assay by serum from participants (n = 20 participants per booster cohort). Sera samples were collected immediately before receiving a booster (day 1) and on days 15 and 29 after the booster dose of mRNA-1273 (50 µg), mRNA-1273.351 (50 or 20 µg) or mRNA-1273.211 (50 µg). Participant sera in the mRNA-1273 (50 µg) booster group were not assessed in the B.1.351 assay. Data are presented as the geometric mean neutralizing antibody titers with 95% confidence intervals. The titers for individual participants are indicated with circles. The fold increases in titers measured at days 15 and 29 versus titers measured before the booster dose are shown. The horizonal dotted lines indicate the LLOQ. Generalized linear model was used to compare neutralization titers among groups; log10 titer was regressed on group, and an individual-specific random effect was included to account for individual specific variability. Two-sided t-test was used for post hoc group comparisons. Sidak’s method was used to adjust the P values for multiple comparisons. Statistical significance was determined at α < 0.01. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NAb, neutralizing antibody.CC BY · PubMed Central
Fig. 4 Neutralization of wild-type D614G and variants by participant serum collected 1 month after primary vaccination series and before and after boosters, as measured by the VSV-based PsVN assay. Sera samples were collected 1 month after the primary series, immediately before receiving the booster dose (6 months after the primary vaccination series) and 2 weeks after the 50-µg booster dose of mRNA-1273 (a), mRNA-1273.351 (b) or mRNA-1273.211 (c). n = 20 for wild-type D614G, B.1.351 and P.1 and n = 11 for B.1.427/B.1.429, B.1.526, B.1.617.1 and B.1.617.2. d, Neutralization of wild-type D614G 1 month after the primary series and neutralization of wild-type D614G, B.1.617.1 and B.1.617.2 immediately before the booster dose from sera samples collected from a subset of participants in the mRNA-1273 booster group (D614G, n = 20; B.1.617.1, n = 11; B.1.617.2, n = 11). In a–d, the GMTs against the wild-type D614G and variants measured in participants before the booster dose or 2 weeks after the booster dose were evaluated versus peak titers measured against the wild-type D614G 1 month after the primary vaccination series. Data are presented as the geometric mean neutralizing antibody titers with 95% confidence intervals. The GMT fold change versus the peak titers against the wild-type D614G virus after the primary vaccination series are shown, with red indicating fold drop and blue indicating fold rise. Results from individual participants are represented as dots on each figure. For all panels, blue colored dots indicate participants whose samples were tested (n = 11), and white dots indicate the remaining participants whose samples were not tested (n = 9). The horizonal dotted line indicates the LLOQ; the solid gray line indicates the within-cohort GMT benchmark. Generalized linear model was used to compare neutralization titers among groups; log10 titer was regressed on group, and an individual-specific random effect was included to account for individual specific variability. Two-sided t-test was used for post hoc group comparisons. Sidak’s method was used to adjust the P values for multiple comparisons. Statistical significance was determined at α < 0.01. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NAb, neutralizing antibody; NS, not significant.
Fig. 4 Neutralization of wild-type D614G and variants by participant serum collected 1 month after primary vaccination series and before and after boosters, as measured by the VSV-based PsVN assay. Sera samples were collected 1 month after the primary series, immediately before receiving the booster dose (6 months after the primary vaccination series) and 2 weeks after the 50-µg booster dose of mRNA-1273 (a), mRNA-1273.351 (b) or mRNA-1273.211 (c). n = 20 for wild-type D614G, B.1.351 and P.1 and n = 11 for B.1.427/B.1.429, B.1.526, B.1.617.1 and B.1.617.2. d, Neutralization of wild-type D614G 1 month after the primary series and neutralization of wild-type D614G, B.1.617.1 and B.1.617.2 immediately before the booster dose from sera samples collected from a subset of participants in the mRNA-1273 booster group (D614G, n = 20; B.1.617.1, n = 11; B.1.617.2, n = 11). In a–d, the GMTs against the wild-type D614G and variants measured in participants before the booster dose or 2 weeks after the booster dose were evaluated versus peak titers measured against the wild-type D614G 1 month after the primary vaccination series. Data are presented as the geometric mean neutralizing antibody titers with 95% confidence intervals. The GMT fold change versus the peak titers against the wild-type D614G virus after the primary vaccination series are shown, with red indicating fold drop and blue indicating fold rise. Results from individual participants are represented as dots on each figure. For all panels, blue colored dots indicate participants whose samples were tested (n = 11), and white dots indicate the remaining participants whose samples were not tested (n = 9). The horizonal dotted line indicates the LLOQ; the solid gray line indicates the within-cohort GMT benchmark. Generalized linear model was used to compare neutralization titers among groups; log10 titer was regressed on group, and an individual-specific random effect was included to account for individual specific variability. Two-sided t-test was used for post hoc group comparisons. Sidak’s method was used to adjust the P values for multiple comparisons. Statistical significance was determined at α < 0.01. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NAb, neutralizing antibody; NS, not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

Sorted by citations

Items 301–375 of 375

Related

See all

Metadata

Authors
Choi, A., Koch, M., Wu, K., Chu, L., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher, J., Colpitts, T., Bennett, H., Legault, H., Paila, Y., Nestorova, B., Ding, B., Montefiori, D., Pajon, R., Miller, J. M., Leav, B., Carfi, A., McPhee, R., & Edwards, D. K.
Affiliations
  • Moderna Therapeutics (United States) (US)
  • Benchmark Research (United States) (US)
  • Duke University (US)
Corresponding author
Edwards, Darin K.
ORCID
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2021-09-15
Volume
27
Issue
11
Pages
2025-2031
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/s41591-021-01527-y
PMC
PMC8604720
OpenAlex
W3200674187
Cited by
396
References
18
Citations by year
2026: 5 · 2025: 27 · 2024: 42 · 2023: 79 · 2022: 202 · 2021: 41
FWCI
28.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Moderna
  • Health Science Center, University of Tennessee
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, COVID-19 vaccines, mRNA-1273, booster vaccination, vaccine safety, immunogenicity, neutralizing antibodies, variants of concern, variants of interest, Beta variant, P.1, Delta variant, antibody waning, D614G
MeSH terms
Immunogenicity, Vaccine, Preliminary Data, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adult, Aged, Antibodies, Viral, Female, Humans, Immunization, Secondary, Male, Middle Aged, RNA, Messenger, United States, Vaccination, Treatment Outcome, Antibodies, Neutralizing, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review